Please login to the form below

Not currently logged in
Email:
Password:

Viralytics

This page shows the latest Viralytics news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Another virus – Viralytics’ Cavatak – showed promise in a phase I trial as a combination with Keytruda in melanoma, piquing Merck’s interest and prompting a $394m takeover deal earlier this year.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....